QOL as an outcome of prostate cancer treatment
Kakehi, Y.
Nihon Rinsho. Japanese Journal of Clinical Medicine 69(Suppl 5): 597-603
2011
ISSN/ISBN: 0047-1852 PMID: 22208051 Document Number: 651167
Document emailed within 1 workday
Related Documents
Wiebe, E.; Rodrigues, G.; Lock, M.; D'Souza, D.; Stitt, L. 2008: Outcome analysis of prostate cancer patients with pre-treatment PSA greater than 50 ng/ml Canadian Journal of Urology 15(3): 4078-4083Fourcade, R-Olivier.; Richaud, P.; Coloby, P.; Malavaud, B. 2007: Role of 150 mg bicalutamide in the treatment of prostate cancer: 3rd analysis of the EPC (early prostate cancer) program Progres en Urologie: Journal de l'Association Francaise d'Urologie et de la Societe Francaise d'Urologie 17(4 Suppl. 1): 891-910
Perez, C.A.; Michalski, J.; Mansur, D. 2005: Clinical assessment of outcome of prostate cancer (TCP, NTCP) Rays 30(2): 109-120
Arap, W. 2008: Quality of life and satisfaction with outcome among prostate-cancer survivors New England Journal of Medicine 359(2): 200
Horiguchi, A.; Hatakeyama, N.; Ikeuchi, K. 1999: Dynamics of prostate-specific antigen as prognostic factors in endocrine treatment for prostate cancer Hinyokika Kiyo. Acta Urologica Japonica 45(1): 31-35
Habib, F.K.; Ross, M.; Bayne, C.W. 1999: Factors controlling the expression of 5alpha-reductase in human prostate: A possible new approach for the treatment of prostate cancer European Urology 35(5-6): 439-442
Bordinazzo, R.; Benecchi, L.; Cazzaniga, A.; Vercesi, A.; Privitera, O. 1994: Ureteral obstruction associated with prostate cancer: the outcome after ultrasonographic percutaneous nephrostomy Archivio Italiano di Urologia Andrologia: Organo Ufficiale di Societa Italiana di Ecografia Urologica e Nefrologica 66(4 Suppl): 101-106
Bejrananda, T.; Pripatnanont, C.; Tanthanuch, M.; Karnjanawanichkul, W. 2016: Oncological Outcome of Docetaxel-Based Chemotherapy for Men with Metastatic Castration-Resistant Prostate Cancer Journal of the Medical Association of Thailand 99(12): 1315-1321
Pai, H.H.; Eldridge, B.; Bishop, D.; Alexander, A.; Lesperance, M.; Blood, P.; Lim, J.; Ludgate, C. 2009: Does neoadjuvant hormone therapy improve outcome in prostate cancer patients receiving radiotherapy after radical prostatectomy? Canadian Journal of Urology 16(2): 4541-4552
Stromberg, J.S.; Martinez, A.A.; Horwitz, E.M.; Gustafson, G.S.; Gonzalez, J.A.; Spencer, W.F.; Brabbins, D.S.; Dmuchowski, C.F.; Hollander, J.B.; Vicini, F.A. 1997: Conformal high dose rate iridium-192 boost brachytherapy in locally advanced prostate cancer: superior prostate-specific antigen response compared with external beam treatment Cancer Journal from Scientific American 3(6): 346-352
Agus, D.B.; Golde, D.W.; Sgouros, G.; Ballangrud, A.; Cordon-Cardo, C.; Scher, H.I. 1998: Positron emission tomography of a human prostate cancer xenograft: association of changes in deoxyglucose accumulation with other measures of outcome following androgen withdrawal Cancer Research 58(14): 3009-3014
Murray, N.P.; Aedo, S.óc.; Reyes, E.; Fuentealba, C.; Jacob, O. 2019: Primary circulating prostate cells, age and prostatic volumen predict the presence of prostate cancer in men with indication of a second prostate biopsy Archivos Espanoles de Urologia 72(1): 16-24
Romppanen, J.; Haapalainen, T.; Punnonen, K.; Penttilä, I. 2002: Serum sialic acid and prostate-specific antigen in differential diagnosis of benign prostate hyperplasia and prostate cancer Anticancer Research 22(1a): 415-420
Sun, S.-C.; Zhao, H.; Liu, R.; Wang, B.-L.; Liu, Y.-Q.; Zhao, Y.; Shi, Z.-D. 2017: Expression of long non-coding RNA H19 in prostate cancer and its effect on the proliferation and glycometabolism of human prostate cancer cells Zhonghua Nan Ke Xue 23(2): 120-124
Considine, B.; Petrylak, D.P. 2019: Integrating Novel Targets and Precision Medicine into Prostate Cancer Care-Part 1: the Non-Androgen-Targetable Pathways in Castration-Resistant Prostate Cancer Oncology 33(3): 113-118
Grosclaude, P.; Menegoz, F.; Schaffer, P.; Macé Lesec'h, J.; Arveux, P.; Le Mab, G.; Soulié, M.; Villers, A. 1997: Prostate cancer screening (II): is prostate cancer a public health problem? Update of incidence and mortality figures in France from 1982 to 1990 Progres en Urologie: Journal de l'Association Francaise d'Urologie et de la Societe Francaise d'Urologie 7(4): 647-654
Ragde, H.; Grado, G.L.; Nadir, B.S. 2001: Brachytherapy for clinically localized prostate cancer: thirteen-year disease-free survival of 769 consecutive prostate cancer patients treated with permanent implants alone Archivos Espanoles de Urologia 54(7): 739-747
Liu, J-he.; Li, H-wei.; Tong, M.; Li, M.; Na, Y-qun. 2004: Genetic risk factors of prostate cancer in Han nationality population in Northern China and a preliminary study of the reason of racial difference in prevalence of prostate cancer Zhonghua Yi Xue Za Zhi 84(5): 364-368
Perrin, P.; François, O.; Maquet, J.H.; Bringeon, G.; Duteil, P.; Devonec, M. 1991: Circulating prostate cancer specific antigens in benign hypertrophy and localized cancer of the prostate Presse Medicale 20(28): 1313-1319
Teodorovich, O.V.; Shatokhin, M.N.; Naryshkin, S.A.; Abdullayev, M.I.; Krasnov, A.V.; Borisenko, G.G.; Zhurbenko, A.A. 2019: Focal laser coagulation in the treatment of a patient with kidney cancer and prostate cancer Urologiia 2: 55-58